News from the Bench
Discover what’s going on at CST, receive our latest application notes and tips, read our science features, and learn about our products.
CST Antibody Performance Guarantee
To Purchase # 8158S
Find answers on our FAQs page.
PTM information and tools available.
Western blot analysis of extracts from Jurkat cells, serum-starved overnight and pretreated with the indicated amounts of SB202190 for 1 hr, and subsequently treated with anisomycin (25 µg/ml, 30 min), using Phospho-p38 MAPK (Thr180/Tyr182) (D3F9) XP® Rabbit mAb #4511 (upper) or p38 MAPK Antibody #9212 (lower).Learn more about how we get our images
Western blot analysis of extracts from Jurkat cells, serum-starved overnight and pretreated with SB202190 (10 µM, 1 hr), and untreated or treated with anisomycin (25 µg/ml, 30 min), using Phospho-MAPKAPK-2 (Thr222) (9A7) Rabbit mAb #3316 (upper) or MAPKAPK-2 Antibody #3042 (lower). MAPKAPK-2 is a specific downstream substrate of p38 MAPK.Learn more about how we get our images
Gallery: SB202190 #8158
SB202190 is supplied as a lyophilized powder. For a 10 mM stock, reconstitute the 5 mg in 1.51 ml DMSO. Working concentrations and length of treatment can vary depending on the desired effect, but it is typically used as a pretreatment at 5-20 µM for 1-2 hours prior to treating with a stimulator. Soluble in DMSO, solubility in other solvents has not been evaluated.Storage: Store lyophilized or in solution at -20ºC, desiccated. Protect from light. In lyophilized form, the chemical is stable for 24 months. Once in solution, use within 3 months to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.
SB202190, a pyridinyl imidazole, inhibits p38 MAP kinase activity through competition with ATP (1), and has been shown to induce apoptosis through activation of cysteine protease (CPP32)-like caspases (2). SB202190 blocks both lipopolysaccharide (LPS)-induced gene expression and nitric oxide (NO)-induced stabilization of interleukin (IL)-8 mRNA in monocytes (3,4). Pre-treatment of cells with SB202190 has been shown to inhibit phosphorylation of p38 MAPK despite exposure to anisomycin, a known inducer of the MAPK pathway (5). Of note, the mechanism of inhibition of SB202190 is unlike the one seen with SB203580, which inhibits p38 MAPK catalytic activity by binding to the ATP binding pocket, but does not inhibit phosphorylation of p38 MAPK by upstream kinases (6).
For Research Use Only. Not For Use In Diagnostic Procedures. Cell Signaling Technology® is a trademark of Cell Signaling Technology, Inc.